The FDA approves the Allurion balloon for weight loss, which is swallowed and doesn't require a procedure for removal. Doctors explain how it works.
Dec. 30, 2025 – updated Jan. 5, 2026 – Injectable GLP-1 drugs have transformed obesity treatment – and now they're going oral. "It's good to have more options for patients with obesity," said Melanie ...
Share on Pinterest The Food and Drug Administration (FDA) recently approved a tablet version of the GLP-1 drug Wegovy for weight loss. Image courtesy of Novo Nordisk Novo Nordisk officials said a new ...
CLEVELAND — As GLP-1 medications continue to gain popularity for weight loss and diabetes management, a local cardiologist is helping patients understand what these drugs can and cannot do. Dr.
For the best results, medications like Ozempic and Zepbound should be combined with exercise and healthy eating habits.
Patients wishing for an alternative to weight loss drug injections now have another option. The U.S. Food and Drug Administration (FDA) recently approved a daily pill form of Wegovy, making it the ...
Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. ON THIS PAGE Featured Partner For years, Ozempic has ...
Bariatric surgery far outperformed GLP-1 weight loss drugs in a new real-world comparison of more than 50,000 patients. Two years after treatment, surgery patients lost about 58 pounds on average, ...
Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including Wegovy and Zepbound are expected to be easier to access and afford. And new ...
Americans now have access to the pill form of weight loss medication Wegovy, Danish drugmaker Novo Nordisk announced on Monday. The oral GLP-1 weight loss medication for adults used to treat obesity ...
The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to ...